TAFETINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H29FN4O2
Molecular Weight	424.5111
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCNC(=O)C1=C(C)NC2=C1CCC\C2=C3\C(=O)NC4=C3C=C(F)C=C4

InChI

InChIKey=KGSRYTUWXUESJK-FXBPSFAMSA-N

InChI=1S/C24H29FN4O2/c1-4-29(5-2)12-11-26-23(30)20-14(3)27-22-16(20)7-6-8-17(22)21-18-13-15(25)9-10-19(18)28-24(21)31/h9-10,13,27H,4-8,11-12H2,1-3H3,(H,26,30)(H,28,31)/b21-17-

HIDE SMILES / InChI

Molecular Formula	C24H29FN4O2
Molecular Weight	424.5111
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:31:35 UTC 2023` Edited by `admin` on `Sat Dec 16 11:31:35 UTC 2023`
Record UNII	H4X2M2NN5N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAFETINIB

Common Name

English

1H-INDOLE-3-CARBOXAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-7-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-4,5,6,7-TETRAHYDRO-2-METHYL-, (7Z)-

Systematic Name

English

SIM-010603

Code

English

SIM 010603

Code

English

(7Z)-N-(2-(DIETHYLAMINO)ETHYL)-7-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-4,5,6,7-TETRAHYDRO-2-METHYL-1H-INDOLE-3-CARBOXAMIDE

Systematic Name

English

(7Z)-N-(2-DIETHYLAMINOETHYL)-7-(5-FLUORO-2-OXO-INDOLIN-3-YLIDENE)-2-METHYL-1,4,5,6-TETRAHYDROINDOLE-3-CARBOXAMIDE

Systematic Name

English

Code System Code Type Description

CAS

1032265-57-8

Created by admin on Sat Dec 16 11:31:35 UTC 2023 , Edited by admin on Sat Dec 16 11:31:35 UTC 2023

PRIMARY

PUBCHEM

56935577

Created by admin on Sat Dec 16 11:31:35 UTC 2023 , Edited by admin on Sat Dec 16 11:31:35 UTC 2023

PRIMARY

FDA UNII

H4X2M2NN5N

Created by admin on Sat Dec 16 11:31:35 UTC 2023 , Edited by admin on Sat Dec 16 11:31:35 UTC 2023

PRIMARY

Related Record Type Details


					H4X2M2NN5N

TAFETINIB

ACTIVE MOIETY

Comments:

The No Observed Adverse Effect Level (NOAEL) of SIM010603 was 5mg/kg/day for rats, and undefined for dogs. The treatment resulted in unscheduled mortality in dogs receiving 10mg/kg of SIM010603 or Sunitinib. The adverse effects of SIM010603 on rats and dogs mainly included gastrointestinal toxicity, skeletal toxicity, myelosuppression, thymus atrophy, bronchopneumonia, cardiovascular dysfunction, and pancreatic toxicity.